Recombinant T-cell receptor ligand RTL1000 limits inflammation and decreases infarct size after experimental ischemic stroke in middle-aged mice

W. Zhu, A. L. Dotson, N. L. Libal, A. S. Lapato, Sheetal Bodhankar, Halina Offner, Nabil Alkayed

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

We have previously demonstrated that recombinant T-cell receptor ligand 1000 (RTL1000) reduces infarct size and improves long-term functional recovery after experimental stroke in young transgenic mice expressing human leukocyte antigen DR2 (DR2-Tg). In this study, we determined the effect of RTL1000 on infarct size in 12-month-old middle-aged DR2-Tg mice, and investigated its mechanism of action. Twelve-month-old male DR2-Tg mice underwent 60min of intraluminal reversible middle cerebral artery occlusion (MCAO). Vehicle or RTL1000 was injected 4, 24, 48 and 72h after MCAO. Cortical, striatal and total hemispheric infarcts were measured 96h after stroke. Spleen and brain tissues were collected 96h after stroke for immunological analysis. Our data showed that RTL1000 significantly reduced infarct size 96h after MCAO in middle-aged male DR2-Tg mice. RTL1000 decreased the number of activated monocytes/microglia cells (CD11b+CD45hi) and CD3+ T cells in the ischemic hemisphere. RTL1000 also reduced the percentage of total T cells and inflammatory neutrophils in the spleen. These findings suggest that RTL1000 protects against ischemic stroke in middle-aged male mice by limiting post-ischemic inflammation.

Original languageEnglish (US)
Pages (from-to)112-119
Number of pages8
JournalNeuroscience
Volume288
DOIs
StatePublished - Mar 2 2015

Fingerprint

T-Cell Antigen Receptor
Stroke
Ligands
Inflammation
Middle Cerebral Artery Infarction
Spleen
T-Lymphocytes
Corpus Striatum
Microglia
HLA Antigens
Transgenic Mice
Monocytes
Neutrophils
Brain

Keywords

  • HLA-DR2 transgenic mice
  • Immunotherapy
  • Ischemic stroke
  • Recombinant T-cell receptor ligand

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Recombinant T-cell receptor ligand RTL1000 limits inflammation and decreases infarct size after experimental ischemic stroke in middle-aged mice. / Zhu, W.; Dotson, A. L.; Libal, N. L.; Lapato, A. S.; Bodhankar, Sheetal; Offner, Halina; Alkayed, Nabil.

In: Neuroscience, Vol. 288, 02.03.2015, p. 112-119.

Research output: Contribution to journalArticle

@article{bba37571b0c24f38a13b40edf5745758,
title = "Recombinant T-cell receptor ligand RTL1000 limits inflammation and decreases infarct size after experimental ischemic stroke in middle-aged mice",
abstract = "We have previously demonstrated that recombinant T-cell receptor ligand 1000 (RTL1000) reduces infarct size and improves long-term functional recovery after experimental stroke in young transgenic mice expressing human leukocyte antigen DR2 (DR2-Tg). In this study, we determined the effect of RTL1000 on infarct size in 12-month-old middle-aged DR2-Tg mice, and investigated its mechanism of action. Twelve-month-old male DR2-Tg mice underwent 60min of intraluminal reversible middle cerebral artery occlusion (MCAO). Vehicle or RTL1000 was injected 4, 24, 48 and 72h after MCAO. Cortical, striatal and total hemispheric infarcts were measured 96h after stroke. Spleen and brain tissues were collected 96h after stroke for immunological analysis. Our data showed that RTL1000 significantly reduced infarct size 96h after MCAO in middle-aged male DR2-Tg mice. RTL1000 decreased the number of activated monocytes/microglia cells (CD11b+CD45hi) and CD3+ T cells in the ischemic hemisphere. RTL1000 also reduced the percentage of total T cells and inflammatory neutrophils in the spleen. These findings suggest that RTL1000 protects against ischemic stroke in middle-aged male mice by limiting post-ischemic inflammation.",
keywords = "HLA-DR2 transgenic mice, Immunotherapy, Ischemic stroke, Recombinant T-cell receptor ligand",
author = "W. Zhu and Dotson, {A. L.} and Libal, {N. L.} and Lapato, {A. S.} and Sheetal Bodhankar and Halina Offner and Nabil Alkayed",
year = "2015",
month = "3",
day = "2",
doi = "10.1016/j.neuroscience.2014.12.037",
language = "English (US)",
volume = "288",
pages = "112--119",
journal = "Neuroscience",
issn = "0306-4522",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Recombinant T-cell receptor ligand RTL1000 limits inflammation and decreases infarct size after experimental ischemic stroke in middle-aged mice

AU - Zhu, W.

AU - Dotson, A. L.

AU - Libal, N. L.

AU - Lapato, A. S.

AU - Bodhankar, Sheetal

AU - Offner, Halina

AU - Alkayed, Nabil

PY - 2015/3/2

Y1 - 2015/3/2

N2 - We have previously demonstrated that recombinant T-cell receptor ligand 1000 (RTL1000) reduces infarct size and improves long-term functional recovery after experimental stroke in young transgenic mice expressing human leukocyte antigen DR2 (DR2-Tg). In this study, we determined the effect of RTL1000 on infarct size in 12-month-old middle-aged DR2-Tg mice, and investigated its mechanism of action. Twelve-month-old male DR2-Tg mice underwent 60min of intraluminal reversible middle cerebral artery occlusion (MCAO). Vehicle or RTL1000 was injected 4, 24, 48 and 72h after MCAO. Cortical, striatal and total hemispheric infarcts were measured 96h after stroke. Spleen and brain tissues were collected 96h after stroke for immunological analysis. Our data showed that RTL1000 significantly reduced infarct size 96h after MCAO in middle-aged male DR2-Tg mice. RTL1000 decreased the number of activated monocytes/microglia cells (CD11b+CD45hi) and CD3+ T cells in the ischemic hemisphere. RTL1000 also reduced the percentage of total T cells and inflammatory neutrophils in the spleen. These findings suggest that RTL1000 protects against ischemic stroke in middle-aged male mice by limiting post-ischemic inflammation.

AB - We have previously demonstrated that recombinant T-cell receptor ligand 1000 (RTL1000) reduces infarct size and improves long-term functional recovery after experimental stroke in young transgenic mice expressing human leukocyte antigen DR2 (DR2-Tg). In this study, we determined the effect of RTL1000 on infarct size in 12-month-old middle-aged DR2-Tg mice, and investigated its mechanism of action. Twelve-month-old male DR2-Tg mice underwent 60min of intraluminal reversible middle cerebral artery occlusion (MCAO). Vehicle or RTL1000 was injected 4, 24, 48 and 72h after MCAO. Cortical, striatal and total hemispheric infarcts were measured 96h after stroke. Spleen and brain tissues were collected 96h after stroke for immunological analysis. Our data showed that RTL1000 significantly reduced infarct size 96h after MCAO in middle-aged male DR2-Tg mice. RTL1000 decreased the number of activated monocytes/microglia cells (CD11b+CD45hi) and CD3+ T cells in the ischemic hemisphere. RTL1000 also reduced the percentage of total T cells and inflammatory neutrophils in the spleen. These findings suggest that RTL1000 protects against ischemic stroke in middle-aged male mice by limiting post-ischemic inflammation.

KW - HLA-DR2 transgenic mice

KW - Immunotherapy

KW - Ischemic stroke

KW - Recombinant T-cell receptor ligand

UR - http://www.scopus.com/inward/record.url?scp=84921026009&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921026009&partnerID=8YFLogxK

U2 - 10.1016/j.neuroscience.2014.12.037

DO - 10.1016/j.neuroscience.2014.12.037

M3 - Article

VL - 288

SP - 112

EP - 119

JO - Neuroscience

JF - Neuroscience

SN - 0306-4522

ER -